发明名称 Method for inducing immune tolerance using viable polymer-modified allogeneic leukocytes
摘要 This invention relates to cellular-based therapies for increasing the level of regulatory T cells (Treg) and/or decreasing the level of pro-inflammatory T cells (Th17) to induce anergy or immune tolerance. To provide these therapeutic effects, two allogeneic leukocyte populations are contacted (in vivo, in vitro or ex vivo) and one of these leukocyte population is modified to bear on its surface a low-immunogenic biocompatible polymer so as to prevent pro-inflammatory allo-recognition. Cellular-based preparations and processes for achieving cellular therapy are also provided.
申请公布号 US9498496(B2) 申请公布日期 2016.11.22
申请号 US201313941303 申请日期 2013.07.12
申请人 CANADIAN BLOOD CERVICES 发明人 Scott Mark D.;Wang Duncheng;Toyofuku Wendy M.
分类号 A01N63/00;A61K35/14;A61K35/17;C12N5/0783;A61K39/00;C12N15/113;A61K9/00;A61K35/00;A61K35/12;A61K47/48 主分类号 A01N63/00
代理机构 Norton Rose Fulbright US LLP 代理人 Norton Rose Fulbright US LLP
主权项 1. A method of inducing increased expansion of endogenous regulatory T cells of a subject for treating or alleviating the symptoms of an auto-immune disease in a subject in need thereof, said method comprising administering to the subject a therapeutic amount of: a cellular preparation consisting of viable leukocytes and a low-immunogenic biocompatible polymer, wherein the low-immunogenic biocompatible polymer is covalently associated with the viable leukocytes, and wherein the viable leukocytes are allogeneic to the subject,wherein the low-immunogenic biocompatible polymer is polyethylene glycol (PEG) or 2-alkyloxazoline (POZ);thereby treating or alleviating the symptoms of the auto-immune disease in the subject.
地址 Ottawa CA